Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Search Results

Title:
G9927 A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and Veliparib (ABT-888) and Bevacizumab in Recurrent Platinum-Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Protocol Number:
G9927
Phase:
Phase I
Physician:
Deborah Armstrong
Purpose:
- To determine the maximum tolerated doses and dose-limiting toxicities of two different regimens of ABT-888 when administered with carboplatin and PLD (Doxil®, Lipodox�) in recurrent, platinum sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer. - To estimate the objective response rate (complete and partial) in patients with measureable disease.
Eligibility:
- platinum sensitive recurrent ovarian cancer - may have an unlimited number of platinum based therapies - may only have one non-platinum therapy in recurrent setting - no prior PARP inhibitors - no prior anti-angiogenic (ie bevacizumab) in recurrent setting - may have measurable disease, detectable disease or biochemical recurrence(elevated CA-125 - good lab values, performace status and organ function
Treatment:
This is an outpatient regimen consisting of two regimens. Both groups will receive IV PLD and IV Carboplatin every 28 days. Both groups will receive ABT-888 orally either on Days 1-7 or Days 1-28 in alternating groups.
Population:
Adult
Last Update
04/17/2014 04:02 AM
 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

 

Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424

NCI CCC

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer